As New Jersey’s only NCI-designated Comprehensive Cancer Center, Rutgers Cancer Institute of New Jersey together with RWJBarnabas Health, provides patients access to the most advanced treatment options including complex surgical procedures, sophisticated radiation therapy techniques, innovative clinical trials, immunotherapy, and precision medicine.
|
|
|
$3.1M Grant from the National Institutes of Health Supports Continued Collaboration on Translational Research |
|
|
|
Immune checkpoint inhibitors are a type of immunotherapy that help the body use its own immune system to fight back against cancer cells. With the support of a $3.1 million grant from the National Institutes of Health, Rutgers Cancer Institute of New Jersey leaders Eileen White, PhD, Edmund Lattime, PhD, and Shridar Ganesan, MD, PhD, will explore the immune response to cancers that feature a high number of mutations. This collaboration on translational research builds on research from a clinical trial led by the Phase 1/Investigational Therapeutics Program at Rutgers Cancer Institute in 2014. The new study aims to make checkpoint inhibitor treatment more responsive for patients. Learn more
|
|
Breastfeeding after Breast Cancer |
|
|
|
Is breastfeeding safe and possible for mothers who have a history of breast cancer? Investigators at Rutgers Cancer Institute of New Jersey recently explored this question by conducting a systematic review on the feasibility and challenges of breastfeeding among breast cancer survivors of reproductive age. Their findings suggest that breastfeeding from the unaffected breast is feasible for some breast cancer survivors. Trishnee Bhurosy, PhD, a researcher in the Cancer Prevention and Control Program at Rutgers Cancer Institute and lead author of the work shares more about these findings. Read more
|
|
Examining a Potential Drug Combination for Liver Cancer Treatment |
|
|
|
Incidence and mortality of hepatocellular carcinoma (HCC), a common type of liver cancer, is increasing in the United States. Rutgers Cancer Institute of New Jersey medical oncologist Kristen Spencer, DO, MPH and researcher X.F. Steven Zheng, PhD, have received a $50,000 award through the Translational Research Pilot Award Program that will support the examination of how a drug combination impacts the growth of both human HCC cancer cells and tumors in laboratory models, with the goal of identifying a new treatment for patients with this disease. Learn more
|
|
Tackle Breast Cancer with Prevention |
|
|
|
While researchers continue to make advancements in cancer detection and treatment for breast cancer, one of the best ways to tackle the disease is through early detection and screening with mammography. Mridula George, MD, medical oncologist in the Stacy Goldstein Breast Cancer Center at Rutgers Cancer Institute of New Jersey, shares more information about risk factors associated with breast cancer and the importance of taking charge of your breast health. Learn more
|
|
Register Now - Beyond Breast Cancer Awareness: A Panel Discussion on Advancements in Breast Cancer Genetics, Research, and Treatment |
|
|
|
On October 27 at 7:00 pm, join Rutgers Cancer Institute of New Jersey experts for a virtual panel discussion hosted by the Rutgers University Alumni Association to learn about advancements in breast cancer research, treatment, and genetics. Panelists include Deborah Toppmeyer, MD, chief medical officer and director of the Stacy Goldstein Breast Cancer Center; Shridar Ganesan, MD, PhD, associate director for translational science and the Omar Boraie Chair in Genomic Science; and Sherry Grumet, MA, MS, LGC, program director of the LIFE Center. Ann M. Stock, PhD, associate director and distinguished professor at Center for Advanced Biotechnology and Medicine at Rutgers University will moderate the discussion. Register here
|
|
|
|
|
|
|
